November 23, 2016 - By Louis Casey
FBR & Co. decreased the shares of Juno Therapeutics (NASDAQ:JUNO) from a “Outperform” rating to “Mkt Perform” rating in a analysts note issued to investors and clients on Wednesday, 23 November. The financial firm now has a $30 PT on company.
Out of 9 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 7 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 78% are positive. $73 is the highest target while $39 is the lowest. The $51.80 average target is 137.94% above today’s ($21.77) stock price. Juno Therapeutics Inc has been the topic of 18 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Suntrust Robinson on Friday, January 29. The company was maintained on Friday, July 8 by FBR Capital. The stock has “Outperform” rating given by FBR Capital on Tuesday, August 18. Northland Capital initiated Juno Therapeutics Inc (NASDAQ:JUNO) rating on Wednesday, July 22. Northland Capital has “Outperform” rating and $64 price target. The firm has “Hold” rating by Standpoint Research given on Thursday, October 29. The firm has “Outperform” rating given on Thursday, June 2 by Raymond James. Barclays Capital initiated the stock with “Equal-Weight” rating in Wednesday, July 6 report. The firm has “Buy” rating by Citigroup given on Thursday, February 25. The firm has “Buy” rating given on Monday, August 24 by Standpoint Research. The company was downgraded on Friday, July 8 by JP Morgan.
About 14.19M shares traded hands or 878.62% up from the average. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 32.60% since April 21, 2016 and is downtrending. It has underperformed by 37.93% the S&P500.
Insitutional Activity: The institutional sentiment increased to 1.4 in Q2 2016. Its up 0.06, from 1.34 in 2016Q1. The ratio increased, as 25 funds sold all Juno Therapeutics Inc shares owned while 36 reduced positions. 23 funds bought stakes while 59 increased positions. They now own 44.56 million shares or 5.68% more from 42.17 million shares in 2016Q1.
Rock Springs Mgmt L P holds 0.56% or 197,001 shares in its portfolio. Teacher Retirement System Of Texas has invested 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). Ny State Common Retirement Fund has 0.01% invested in the company for 123,865 shares. Mutual Of America Cap Management holds 0% or 1,370 shares in its portfolio. Aqr Mngmt Ltd Llc last reported 0.02% of its portfolio in the stock. Teachers Advisors Inc accumulated 0% or 52,548 shares. Ubs Asset Management Americas accumulated 35,464 shares or 0% of the stock. First Tru Advsrs Lp has 0.09% invested in the company for 703,197 shares. Baillie Gifford reported 10.84M shares or 0.74% of all its holdings. First Republic accumulated 0% or 5,935 shares. Natl Bank Of America De holds 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 39,016 shares. The Pennsylvania-based Vanguard Inc has invested 0.01% in Juno Therapeutics Inc (NASDAQ:JUNO). Citadel Ltd Com holds 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 41,119 shares. Swiss Bancorporation accumulated 79,900 shares or 0% of the stock. Suffolk Capital Management Ltd Llc holds 0.32% or 65,514 shares in its portfolio.
Juno Therapeutics, Inc. is a biopharmaceutical firm focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The company has a market cap of $2.19 billion. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.
According to Zacks Investment Research, “Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.”
Juno Therapeutics, Inc. (Juno), incorporated on August 5, 2013, is a biopharmaceutical firm focused on re-engaging the bodyâ€™s immune system to revolutionize the treatment of cancer. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.
More recent Juno Therapeutics Inc (NASDAQ:JUNO) news were published by: Fortune.com which released: “Juno Therapeutics: Shares Sink After More Drug Trial Deaths” on November 23, 2016. Also Marketwatch.com published the news titled: “UPDATE: Juno Therapeutics plummets 30% in pre-market trade after two patient …” on November 23, 2016. Fool.com‘s news article titled: “Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics” with publication date: November 03, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Louis Casey